Please wait a minute...
文章检索
预防医学  2021, Vol. 33 Issue (2): 143-148    DOI: 10.19485/j.cnki.issn2096-5087.2021.02.009
  综述 本期目录 | 过刊浏览 | 高级检索 |
新型冠状病毒肺炎疫苗研究进展
朱瑶1, 韦意娜2, 孙畅3 综述, 何寒青1 审校
1.浙江省疾病预防控制中心免疫规划所,浙江 杭州 310051;
2.义乌市疾病预防控制中心免疫规划科;
3.厦门大学公共卫生学院
Development of vaccines against COVID-19
ZHU Yao*, WEI Yina, SUN Chang, HE Hanqing
*Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China
全文: PDF(850 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 新型冠状病毒肺炎(新冠肺炎)疫情暴发以来,世界各国加快了新型冠状病毒肺炎疫苗(新冠疫苗)研制。截至2020年12月,已经有60个候选新冠疫苗批准进入临床试验,其中7个疫苗(灭活疫苗3个、mRNA核酸疫苗2个、载体疫苗2个)获批紧急使用或附条件上市。本文对灭活疫苗、核酸疫苗、载体疫苗、蛋白亚单位疫苗、减毒活疫苗和病毒样颗粒疫苗6种新冠疫苗技术路线的研制进展和优缺点进行综述。现有研究结果表明,进入Ⅲ期临床试验的新冠疫苗均有较好的安全性和免疫原性,获批使用的疫苗临床试验已证实了具有良好的保护效力;但仍需关注疫苗的不良反应并追踪评估长期保护效果,以制定完善的免疫策略遏制新冠肺炎疫情。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
朱瑶
韦意娜
孙畅
何寒青
关键词 新型冠状病毒新型冠状病毒肺炎疫苗临床试验研究进展    
Abstract:Since coronavirus disease 2019 (COVID-19) broke out, the world has accelerated the development of preventive vaccines. By December 2020, 60 candidate vaccines have been approved for clinical trials, of which 7 vaccines, including 3 inactivated vaccines, 2 mRNA vaccines and 2 vector vaccines, have been authorized for emergency use or conditional marketing. In this paper, we reviewed the development progress in inactivated vaccines, nucleic acid vaccines, vector vaccines, protein subunit vaccines, attenuated vaccines and virus-like particle vaccines, as well as advantages and disadvantages of these vaccines. The studies showed that the vaccines against COVID-19 in phase III clinical trials had good safety and immunogenicity, and those authorized vaccines were declared to have good efficacy. However, attention should be paid to the adverse reactions of the vaccines and the long-term protective effects, in order to improve the immunization strategy for the control of COVID-19 epidemic.
Key wordssevere acute respiratory syndrome coronavirus 2    coronavirus disease 2019    vaccine    clinical trial    development progress
收稿日期: 2020-12-10      出版日期: 2021-02-01
ZTFLH:  R186  
基金资助:国家社科基金项目(20CGL054)
通信作者: 何寒青,E-mail:hanqinghe@cdc.zj.cn   
作者简介: 朱瑶,医师,硕士,主要从事免疫针对传染病防控策略研究
引用本文:   
朱瑶, 韦意娜, 孙畅, 何寒青. 新型冠状病毒肺炎疫苗研究进展[J]. 预防医学, 2021, 33(2): 143-148.
ZHU Yao, WEI Yina, SUN Chang, HE Hanqing. Development of vaccines against COVID-19. Preventive Medicine, 2021, 33(2): 143-148.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2021.02.009      或      http://www.zjyfyxzz.com/CN/Y2021/V33/I2/143
[1] World Health Organization.Coronavirus disease (COVID-19) pandemic[EB/OL].[2021-01-07]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
[2] DAI L,GAO G F. Viral targets for vaccines against COVID-19[J/OL]. Nat Rev Immunol(2020-12-18) [2021-01-07].https://www.nature.com/articles/s41577-020-00480-0.DOI: 10.1038/s41577-020-00480-0.
[3] World Health Organization.DRAFT landscape of COVID-19 candidate vaccines[EB/OL]. [2021-01-07].https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
[4] 邓强,王子晨,吴沁,等. 新型冠状病毒疫苗的研究进展[J]. 暨南大学学报(自然科学与医学版),2020,41(6):511-519.
[5] MULLIGAN M J.An inactivated virus candidate vaccine to prevent COVID-19[J]. JAMA,2020,324(10):943-945.
[6] KAUR S P,GUPTA V. COVID-19 vaccine:a comprehensive status report[J/OL]. Virus Res,2020,288[2021-01-07].https://www.researchgate.net/publication/343630942_COVID-19_Vaccine_A_comprehensive_status_report.DOI:10.1016/j.virusres.2020.
198114.
[7] 甄永苏,赵铠. 疫苗研究与应用[M]. 北京:人民卫生出版社,2013.
[8] XIA S,ZHANG Y,WANG Y,et al.Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,BBIBP-CorV:a randomised,double-blind,placebo-controlled,phase 1/2 trial[J]. Lancet Infect Dis,2020,21(1):39-51.
[9] ZHANG Y,ZENG G,PAN H,et al. Safety,tolerability,and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years:a randomised,double-blind,placebo-controlled,phase 1/2 clinical trial[J/OL]. Lancet Infect Dis(2020-11-17)[2021-01-07].https://www.sciencedirect.com/science/article/pii/S1473309920308434.
[10] UAE Ministry of Health and Prevention announces official registration of inactivated COVID-19 vaccine used in #4Humanity Trials[EB/OL].(2020-12-09)[2021-01-07]. http://www.wam.ae/ar/details/1395302893588.
[11] 国务院新闻办公室. 国务院联防联控机制举行新冠病毒疫苗附条件上市及相关工作情况发布会[EB/OL].[2021-01-07]. http://www.scio.gov.cn/xwfbh/xwbfbh/wqfbh/42311/44679/index.htm.
[12] KUTZLER M A,WEINER D B.DNA vaccines:ready for prime time?[J]. Nat Rev Genet,2008,9(10):776-788.
[13] PARDI N,HOGAN M J,PORTER F W,et al.mRNA vaccines-a new era in vaccinology[J]. Nat Rev Drug Discov,2018,17(4):261-279.
[14] SUSCHAK J J,WILLIAMS J A,SCHMALJOHN C S.Advancements in DNA vaccine vectors,non-mechanical delivery methods,and molecular adjuvants to increase immunogenicity[J]. Human Vaccines Immunother,2017,13(12):2837-2848.
[15] MASCOLA J R,FAUCI A S.Novel vaccine technologies for the 21st century[J]. Nat Rev Immunol,2020,20(2):87-88.
[16] POLACK F P,THOMAS S J,KITCHIN N,et al.Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine[J]. N Engl J Med,2020,383(27):2603-2615.
[17] BADEN L R,EL SAHLY H M,ESSINK B,et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine[J/OL]. N Engl J Med(2020-12-30)[2021-01-07].https://www.researchgate.net/publication/348086310_Efficacy_and_Safety_of_the_mRNA-1273_SARS-CoV-2_Vaccine.DOI:10.1056/NEJMoa2035389.
[18] WIDGE A T,ROUPHAEL N G,JACKSON L A,et al.Durability of responses after SARS-CoV-2 mRNA-1273 vaccination
[J/OL]. N Engl J Med,384(1):80-82.
[19] Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee Meeting December 10,2020-FDA[EB/OL]. [2021-01-07]. https://www.fda.gov/media/144245/download.
[20] Food and Drug Administration. COVID-19 vaccines authorized for emergency use[EB/OL].[2021-01-07].https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines.
[21] INOVIO announces initiation of phase 2 segment of its phase 2/3 clinical trial for its COVID-19 DNA vaccine candidate,INO-4800;trial will be funded by the U.S.Department of Defense[EB/OL]. [2021-01-07].http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Initiation-of-Phase-2-Segment-of-its-Phase-23-Clinical-Trial-for-its-COVID-19-DNA-Vaccine
Candidate-INO-4800-Trial-Will-Be-Funded-by-the-U.S.-Department-of-Defense/default.aspx.
[22] INOVIO announces positive interim phase 1 data for INO-4800 vaccine for COVID-19[EB/OL]. [2021-01-07].http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine
for-COVID-19/default.aspx.
[23] Safety,immunogenicity,and efficacy of INO-4800 for COVID-19 in healthy seronegative adults at high risk of SARS-CoV-2 exposure[EB/OL].[2021-01-07].https://clinicaltrials.gov/ct2/show/NCT04642638.
[24] 成传刚,慕婷,袁军,等. 重组病毒载体疫苗研究进展[J]. 中国病毒病杂志,2018,8(4): 318-328.
[25] 柳云帆. 一种新的复制缺陷型腺病毒载体系统的组建[D].北京:中国疾病预防控制中心,2011.
[26] AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19[EB/OL]. [2021-01-07].https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html.
[27] Merck's ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] granted conditional approval in the European Union[EB/OL]. [2021-01-07].https://www.businesswire.com/news/home/20191111005601/en/Merck%E2%80%99s-ERVEBO%C2%AE-Ebola-Zaire-Vaccine-rVSV%CE%94G-ZEBOV-GP-live.
[28] ZHU F C,GUAN X H,LI Y H,et al.Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older:a randomised,double-blind,placebo-controlled,phase 2 trial[J]. Lancet,2020,396(10249):479-488.
[29] VOYSEY M,CLEMENS S A C,MADHI S A,et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2:an interim analysis of four randomised controlled trials in Brazil,South Africa,and the UK[J]. Lancet,397(10269):99-111.
[30] Sputnik V Press Releases[EB/OL]Sputnik V Press Releases[EB/OL]. [2021-01-07]. https://sputnikvaccine.com/newsroom/pressreleases/.
[31] SADOFF J,LE GARS M,SHUKAREV G,et al. Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate:interim results 1 of a phase 1/2a,double-blind,randomized,placebo-controlled trial[EB/OL].[2021-01-07].https://doi.org/10.1101/2020.09.23.20199604.
[32] 宋全伟,王华庆. 不同技术路线研发新型冠状病毒疫苗的特性和研究进展[J]. 中华医学杂志,2020,100(38):3030-3040.
[33] KEECH C,ALBERT G,CHO I,et al.Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine[J]. N Engl J Med,2020,383(24):2320-2332.
[34] YANG S L,LI Y,DAI L P,et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults:pooled analysis of two randomized,double-blind,placebo-controlled,phase 1 and 2 trials[EB/OL].[2021-01-07].https://doi.org/10.1101/2020.12.20.20248602.
[35] 李焱琳. 病毒样颗粒疫苗的免疫机制研究及应用进展[J]. 国际生物制品学杂志,2019,42(4): 203-208.
[36] 郭慧敏,缪秋红,谭永贵,等. 病毒样颗粒的常用表达系统和应用进展[J]. 中国动物传染病学报,2017,25(4):82-86.
[37] WARD B J,GOBEIL P,SÉGUIN A,et al. Phase 1 trial of a candidate recombinant virus-like particle vaccine for Covid-19 disease produced in plants. [EB/OL].[2021-01-07].https://doi.org/10.1101/2020.11.04.20226282.
[38] GARBER K. Coronavirus vaccine developers wary of errant antibodies[J/OL]. Nat Biotechnol(2020-06-05)[2021-01-07].https://www.researchgate.net/publication/341951939_Coronavirus_vaccine_developers_wary_of_errant_antibodies.DOI:10.1038/d41587-020-00016-w.
[39] AGRAWAL A S,TAO X,ALGAISSI A,et al.Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus[J]. Human Vaccines Immunother,2016,12(9):2351-2356.
[40] WAN Y,SHANG J,SUN S,et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry[J/OL]. J Virol,2020,94(5)[2021-01-07].https://www.researchgate.net/publication/337899543_Molecular_Mechanism_for_Antibody-Dependent_Enhancement_of_Coronavirus_Entry.DOI:10.1128/JVI.
02015-19.
[41] ZHU F C,LI Y H,GUAN X H,et al.Safety,tolerability,and immunogenicity of a recombinant adenovirus type-5 vectored
COVID-19 vaccine:a dose-escalation,open-label,non-randomised,first-in-human trial[J]. Lancet,2020,395(10240):1845-1854.
[42] FOLEGATTI P M,EWER K J,ALEY P K,et al.Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against
SARS-CoV-2:a preliminary report of aphase 1/2,single-blind,randomised controlled trial[J]. Lancet,2020,396(10249):467-478.
[43] World Health Organization.WHO target product profiles for
COVID-19 vaccines[R]. Geneva:World Health Organization,2020.
[44] HODGSON S H,MANSATTA K,MALLETT G,et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2[J/OL]. Lancet Infect Dis(2020-10-27)[2021-01-07].https://doi.org/10.1016/S1473-3099(20)30773-8.
[45] Pfizer and BioNTech celebrate historic first authorization in the U.S. of vaccine to prevent COVID-19[EB/OL]. (2020-12-31)[2021-01-07]. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-celebrate-historic-first-authorization.
[46] Moderna's COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE Study[EB/OL]. (2020-12-02)[2021-01-07]. https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy.
[47] 我国5家正进行Ⅲ期临床试验的疫苗企业的产能将共达到20亿剂[EB/OL]. (2020-12-31)[2021-01-07]. https://news.sina.com.cn/o/2020-12-19/doc-iiznctke7398414.shtml.
[48] THANH LE T,ANDREADAKIS Z,KUMAR A, et al.The
COVID-19 vaccine development landscape[J]. Nat Rev Drug Discov,2020,19(5):305-306.
[49] GRUBAUGH N D,HANAGE W P,RASMUSSEN A L.Making sense of mutation:what D614G means for the COVID-19 pandemic remains unclear[J]. Cell,2020,182(4):794-795.
[1] 季巧英, 陶桃, 邱理杨, 叶先明, 董升草, 夏永玲, 吴振宇, 陈秀英. 丽水市首起新型冠状病毒肺炎聚集性疫情调查[J]. 预防医学, 2021, 33(1): 72-74.
[2] 钟若曦, 屠鸿薇, 康敏, 李艳, 刘勇鹰, 郭丽丽, 曾尧, 宋铁, 黄琼. 广东省居民新型冠状病毒肺炎相关知识调查[J]. 预防医学, 2021, 33(1): 91-93.
[3] 陈橙, 夏云丽, 孙亚军, 雷鹏, 肖伦. 九龙坡区新型冠状病毒肺炎病例密切接触者特征分析[J]. 预防医学, 2020, 32(9): 882-885.
[4] 程芳, 刘赛朵, 叶新春, 郑世林, 吴特, 张强, 施伎蝉. 新型冠状病毒肺炎普通型和重症病例临床特征比较[J]. 预防医学, 2020, 32(9): 886-890.
[5] 王宇红, 张薇, 张晓宇, 马汉平, 王昭君, 张艳, 苏延军, 李红蓉. 兰州市报告的首起新型冠状病毒肺炎家庭聚集性疫情调查[J]. 预防医学, 2020, 32(9): 891-894.
[6] 李辉, 段东辉, 陈冰冰, 孙嘉璐, 丁克琴, 易波, 袁薇薇, 夏胡, 张栋梁, 李宁, 雷松, 崔军. 宁波市一起新型冠状病毒肺炎家庭聚集性疫情调查[J]. 预防医学, 2020, 32(9): 895-898.
[7] 孙品晶, 董莹, 李清, 陈晨, 李敏超. 海宁市老年人流感疫苗接种效果评价[J]. 预防医学, 2020, 32(9): 929-932.
[8] 王凌虹, 叶莉霞, 顾永权, 方挺. 余姚市2012—2018年出生儿童肠道病毒71型疫苗接种分析[J]. 预防医学, 2020, 32(9): 911-913.
[9] 叶莹, 范威, 王文华, 申晓靖, 张肖肖, 潘静静, 王海峰, 黄学勇. 河南省新型冠状病毒肺炎家庭聚集性疫情流行特征[J]. 预防医学, 2020, 32(8): 782-786.
[10] 王吉玲, 马岩, 方益荣, 徐来潮, 许树红, 刘明奇. 绍兴市新型冠状病毒肺炎病例流行特征分析[J]. 预防医学, 2020, 32(8): 787-789.
[11] 韩宗梅, 徐校平, 顾丽华, 潘爱珍, 李敏红. 浙江省疫苗管理的SWOT分析[J]. 预防医学, 2020, 32(7): 655-658.
[12] 刘昊晖, 覃健敏, 农皓, 蒋作祎. 南宁市新型冠状病毒肺炎聚集性疫情流行特征分析[J]. 预防医学, 2020, 32(7): 674-677.
[13] 吴群, 曾小平, 王明昌, 陈琴, 李永武, 郑志敬, 吴维学. 海口市一起潜伏期新型冠状病毒肺炎病例引起的聚集性疫情分析[J]. 预防医学, 2020, 32(7): 670-673.
[14] 倪晓媚, 柯珍, 季小微, 洪久洋, 卢远建, 朱周威, 曾永, 朱海博. 青田县一起境外输入新型冠状病毒肺炎聚集性疫情分析[J]. 预防医学, 2020, 32(7): 678-681.
[15] 许玉洋, 刘艳, 张小平, 杜渐, 车鑫仁, 王骏, 顾雯雯, 张学潮, 江伟. 杭州市2~11岁儿童水痘减毒活疫苗接种情况调查[J]. 预防医学, 2020, 32(7): 689-691.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed